Contribute to the Site - OT

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Jessica Cheng, MD

Novel PI3Kα Inhibitor Combo Shows Meaningful PFS in HR+/HER2– Breast Cancer

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

NeoCOAST-2 Data Show Pathologic Responses Across Various Combos in NSCLC

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.

Megan Hollasch

Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC

In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

Referrals From Community to Academia Enhances Multiple Myeloma Outcomes

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

Related Content

Samer A. Al'Hadidi, MD;Frits van Rhee, MD, PhD;Appalanaidu Sasapu, MD

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Jessica Cheng, MD

Novel PI3Kα Inhibitor Combo Shows Meaningful PFS in HR+/HER2– Breast Cancer

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

NeoCOAST-2 Data Show Pathologic Responses Across Various Combos in NSCLC

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Megan Hollasch

Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC

In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.